Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Targeting acute myeloid leukemia stem cell signaling by natural products.

Siveen KS, Uddin S, Mohammad RM.

Mol Cancer. 2017 Jan 30;16(1):13. doi: 10.1186/s12943-016-0571-x. Review.

2.

Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia.

Mosna F, Gottardi M.

Stem Cells Int. 2016;2016:7625827. doi: 10.1155/2016/7625827. Epub 2016 Jan 13. Review.

3.

Overexpression and knockout of miR-126 both promote leukemogenesis.

Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J.

Blood. 2015 Oct 22;126(17):2005-15. doi: 10.1182/blood-2015-04-639062. Epub 2015 Sep 11.

4.

Electrically-driven modulation of surface-grafted RGD peptides for manipulation of cell adhesion.

Lashkor M, Rawson FJ, Stephenson-Brown A, Preece JA, Mendes PM.

Chem Commun (Camb). 2014 Dec 21;50(98):15589-92. doi: 10.1039/c4cc06649a. Epub 2014 Oct 31.

5.

The Biology and Targeting of FLT3 in Pediatric Leukemia.

Annesley CE, Brown P.

Front Oncol. 2014 Sep 23;4:263. doi: 10.3389/fonc.2014.00263. eCollection 2014. Review.

6.

Distinct stromal cell factor combinations can separately control hematopoietic stem cell survival, proliferation, and self-renewal.

Wohrer S, Knapp DJ, Copley MR, Benz C, Kent DG, Rowe K, Babovic S, Mader H, Oostendorp RA, Eaves CJ.

Cell Rep. 2014 Jun 26;7(6):1956-67. doi: 10.1016/j.celrep.2014.05.014. Epub 2014 Jun 6.

7.

Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1.

Bu Y, Jia QA, Ren ZG, Zhang JB, Jiang XM, Liang L, Xue TC, Zhang QB, Wang YH, Zhang L, Xie XY, Tang ZY.

PLoS One. 2014 Mar 14;9(3):e89686. doi: 10.1371/journal.pone.0089686. eCollection 2014.

8.

GPCRs in stem cell function.

Doze VA, Perez DM.

Prog Mol Biol Transl Sci. 2013;115:175-216. doi: 10.1016/B978-0-12-394587-7.00005-1. Review.

9.

Herbal Compound "Songyou Yin" Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness.

Jia QA, Ren ZG, Bu Y, Wang ZM, Zhang QB, Liang L, Jiang XM, Zhang QB, Tang ZY.

Evid Based Complement Alternat Med. 2012;2012:908601. doi: 10.1155/2012/908601. Epub 2012 Dec 20.

10.

Role of autophagy in acute myeloid leukemia therapy.

Zhang SP, Niu YN, Yuan N, Zhang AH, Chao D, Xu QP, Wang LJ, Zhang XG, Zhao WL, Zhao Y, Wang JR.

Chin J Cancer. 2013 Mar;32(3):130-5. doi: 10.5732/cjc.012.10073. Epub 2012 Aug 2. Review.

11.

Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.

Quintana-Bustamante O, Lan-Lan Smith S, Griessinger E, Reyal Y, Vargaftig J, Lister TA, Fitzgibbon J, Bonnet D.

Leukemia. 2012 Jul;26(7):1537-46. doi: 10.1038/leu.2012.38. Epub 2012 Feb 10.

12.

Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties.

Chen SF, Chang YC, Nieh S, Liu CL, Yang CY, Lin YS.

PLoS One. 2012;7(2):e31864. doi: 10.1371/journal.pone.0031864. Epub 2012 Feb 16.

13.

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Walter RB, Appelbaum FR, Estey EH, Bernstein ID.

Blood. 2012 Jun 28;119(26):6198-208. doi: 10.1182/blood-2011-11-325050. Epub 2012 Jan 27. Review.

14.

Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype.

Didier C, Demur C, Grimal F, Jullien D, Manenti S, Ducommun B.

Cancer Biol Ther. 2012 Mar;13(5):307-13. doi: 10.4161/cbt.19074. Epub 2012 Mar 1.

15.

Novel agents inhibit human leukemic cells.

Yu WP, Li J.

Acta Pharmacol Sin. 2012 Feb;33(2):210-1. doi: 10.1038/aps.2011.207. Epub 2012 Jan 9. No abstract available.

16.

Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia.

Thomas X.

World J Stem Cells. 2009 Dec 31;1(1):49-54. doi: 10.4252/wjsc.v1.i1.49.

17.

Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid.

Li H, Lu Y, Piao L, Wu J, Liu S, Marcucci G, Ratnam M, Lee RJ.

Int J Pharm. 2010 Dec 15;402(1-2):57-63. doi: 10.1016/j.ijpharm.2010.09.019. Epub 2010 Sep 29.

18.

SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.

Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, Srour EF, Nakshatri H.

BMC Cancer. 2010 Aug 6;10:411. doi: 10.1186/1471-2407-10-411.

19.

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.

Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW.

Genes Dev. 2010 Jul 1;24(13):1389-402. doi: 10.1101/gad.1940710.

20.

Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.

Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, Croce CM, Stein GS.

Cancer Res. 2009 Nov 1;69(21):8249-55. doi: 10.1158/0008-5472.CAN-09-1567. Epub 2009 Oct 13.

Supplemental Content

Support Center